Search company, investor...

Predict your next investment

Venture Capital
bioventure.com.cn

Investments

165

Portfolio Exits

15

Funds

2

Partners & Customers

3

About bioVENTURE

Suzhou Industrial Park Bioventure Investment Management (苏州元生创投), dba bioVENTURE (元生创投), is an early-stage venture capital firm that focuses on life sciences.

Headquarters Location

Suzhou Industrial Park 218 A1 Building 2 / F, North E37 Unit

Suzhou, Jiangsu, 215123,

China

+86 512 6288 6525

Want to inform investors similar to bioVENTURE about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest bioVENTURE News

Saudi-based AJA Pharma and the UAE’s Bioventure agree deal to license and supply new pharmaceuticals

Feb 2, 2023

and now with the details Jeddah - Yasmine El Tohamy - RIYADH: The Saudi Central Bank has increased its interest rate by 25 basis points to 5.25 percent, echoing Wednesday’s move by the US Federal Reserve to curb inflation. A statement from the bank, also known as SAMA, noted its Reverse Repo rate has also increased to 4.75 percent. Inflation is on the rise in the Kingdom, with the annual rate rising to 3.3 percent in December, up from 2.9 percent in November. The Fed’s quarter-point interest rate hike follows months of larger increases, as it hiked 50 basis points in December, and 75 basis points in November, September, July and June. Despite recent signs of a slow down in the US economy, prices are running at their highest level since the early 1980s. While the US Central Bank’s decision was driven by its desire to lower high inflation, this played a part in driving the Gulf region’s monetary policy, as most of the region’s currencies are pegged to the dollar. Following the US Fed’s decision, regional central banks also swung into action to raise their interest rates – although Qatar chose to hold. The UAE's central bank increased its base rate to 4.65 percent, effective on Thursday, while the Central Bank of Oman hiked its Repo rate to reach 5.25 percent. Bahrain also raised its main rate by 25 basis points, with its one-week deposit facility rate rising to 5.5 percent, while the overnight deposit rate hit 5.25 percent. Qatar’s Central Bank said in a press release Wednesday that it would keep its rates unchanged, keeping its deposit rate at 5 percent, its lending rate at 5.5 percent, and its repo rates at 5.25 percent. As it was predicted that the country would mirror the Fed in early 2023 by the credit ratings agency Fitch in a report last month, this decision came somewhat as a surprise. The Central Bank of Kuwait, which raised its interest rate by 50 basis points last month, often acts separately and does not necessarily follow the Fed’s hikes. In addition, the Central Bank of Egypt is forecast to raise its overnight interest rates by 150 basis points at its regular monetary policy committee meeting on Thursday, a Reuters poll showed last Monday. The CBE increased its interest rates by an unprecedented 800 basis points over the last year alone, and has been involved in a constant series of currency devaluations. A poll of 13 analysts anticipated the bank to increase its deposit rate to 17.75 percent and its lending rate to 18.75 percent. These were the details of the news Saudi-based AJA Pharma and the UAE’s Bioventure agree deal to license and supply new pharmaceuticals for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new. It is also worth noting that the original news has been published and is available at Arab News and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

bioVENTURE Investments

165 Investments

bioVENTURE has made 165 investments. Their latest investment was in Eyedeal as part of their Series B on April 4, 2023.

CBI Logo

bioVENTURE Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/23/2023

Series B

Eyedeal

Yes

4

2/16/2023

Series A

Yingnuo Medical Technology

Yes

4

1/30/2023

Series A - II

Yuzhibo

Yes

1

1/17/2023

Series B

Subscribe to see more

Subscribe to see more

10

1/4/2023

Series A

Subscribe to see more

Subscribe to see more

10

Date

4/23/2023

2/16/2023

1/30/2023

1/17/2023

1/4/2023

Round

Series B

Series A

Series A - II

Series B

Series A

Company

Eyedeal

Yingnuo Medical Technology

Yuzhibo

Subscribe to see more

Subscribe to see more

Amount

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

4

1

10

10

bioVENTURE Portfolio Exits

15 Portfolio Exits

bioVENTURE has 15 portfolio exits. Their latest portfolio exit was Cryofocus Medtech on December 30, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/30/2022

IPO

$99M

Public

1

12/30/2022

IPO

$99M

Public

4

11/28/2022

IPO

$99M

Public

1

7/28/2022

IPO

Subscribe to see more

$99M

Subscribe to see more

10

3/31/2022

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/30/2022

12/30/2022

11/28/2022

7/28/2022

3/31/2022

Exit

IPO

IPO

IPO

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Public

Public

Subscribe to see more

Subscribe to see more

Sources

1

4

1

10

10

bioVENTURE Fund History

2 Fund Histories

bioVENTURE has 2 funds, including YuanBio Venture Capital LP.

Closing Date

Fund

Fund Type

Status

Amount

Sources

3/30/2018

YuanBio Venture Capital LP

Early-Stage Venture Capital

Open

1

Suzhou Industrial Park Xinjianyuan Biological Venture Capital Fund II LP

Subscribe to see more

Subscribe to see more

10

Closing Date

3/30/2018

Fund

YuanBio Venture Capital LP

Suzhou Industrial Park Xinjianyuan Biological Venture Capital Fund II LP

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Status

Open

Subscribe to see more

Amount

Sources

1

10

bioVENTURE Partners & Customers

3 Partners and customers

bioVENTURE has 3 strategic partners and customers. bioVENTURE recently partnered with Alvotech on November 11, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

11/29/2022

Licensor

Iceland

Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa

According to the agreement , Minapharm Pharmaceuticals and MiGenTra GmbH will share responsibilities in the Territory to file , launch and commercialize Alvotech 's portfolio of licensed biosimilars once approved , under Bioventure 's exclusive strategic partnership with Alvotech in the region .

6

10/1/2022

Licensor

Iceland

Subscribe to see more

Subscribe to see more

10

3/3/2022

Licensee

France

Subscribe to see more

Subscribe to see more

10

Date

11/29/2022

10/1/2022

3/3/2022

Type

Licensor

Licensor

Licensee

Business Partner

Country

Iceland

Iceland

France

News Snippet

Bioventure, Minapharm Pharmaceuticals and MiGenTra Sign an Exclusive Agreement for the Commercialization of Multiple Biosimilar Candidates of Alvotech in the Middle East and Africa

According to the agreement , Minapharm Pharmaceuticals and MiGenTra GmbH will share responsibilities in the Territory to file , launch and commercialize Alvotech 's portfolio of licensed biosimilars once approved , under Bioventure 's exclusive strategic partnership with Alvotech in the region .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

6

10

10

bioVENTURE Team

1 Team Member

bioVENTURE has 1 team member, including current Managing Partner, Jie Chen.

Name

Work History

Title

Status

Jie Chen

Managing Partner

Current

Name

Jie Chen

Work History

Title

Managing Partner

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.